Nevertheless, we do not know the OHSS risk among BEYOND trial participants with AMH 23–35 pmol/l as we did not prespecify a subanalysis of participants with baseline AMH 23–35 pmol/l, or those diagnosed with PCOS. This evidence concerns the gene AMH and ovarian hyperstimulation syndrome.